Nature Communications (Nov 2019)
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
- Lei Nie,
- Yongkun Wei,
- Fei Zhang,
- Yi-Hsin Hsu,
- Li-Chuan Chan,
- Weiya Xia,
- Baozhen Ke,
- Cihui Zhu,
- Rong Deng,
- Jun Tang,
- Jun Yao,
- Yu-Yi Chu,
- Xixi Zhao,
- Ye Han,
- Junwei Hou,
- Longfei Huo,
- How-Wen Ko,
- Wan-Chi Lin,
- Hirohito Yamaguchi,
- Jung-Mao Hsu,
- Yi Yang,
- Dean N. Pan,
- Jennifer L. Hsu,
- Celina G. Kleer,
- Nancy E. Davidson,
- Gabriel N. Hortobagyi,
- Mien-Chie Hung
Affiliations
- Lei Nie
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Yongkun Wei
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Fei Zhang
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Yi-Hsin Hsu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Li-Chuan Chan
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Weiya Xia
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Baozhen Ke
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Cihui Zhu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Rong Deng
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Jun Tang
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Jun Yao
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Yu-Yi Chu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Xixi Zhao
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Ye Han
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Junwei Hou
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Longfei Huo
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- How-Wen Ko
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Wan-Chi Lin
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Hirohito Yamaguchi
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Jung-Mao Hsu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Yi Yang
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Dean N. Pan
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Jennifer L. Hsu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- Celina G. Kleer
- Department of Pathology, University of Michigan Medical School
- Nancy E. Davidson
- Fred Hutchinson Cancer Research Center
- Gabriel N. Hortobagyi
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center Houston
- Mien-Chie Hung
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-019-13105-5
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 15
Abstract
EZH2 phosphorylation by CDK2 promotes progression of triple-negative breast cancer (TNBC). Here, the authors show that this signaling axis downregulates ERα, and thus combinatorial blockade of CDK2 and EZH2 sensitizes TNBC cells to tamoxifen.
